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Contrast-induced nephropathy (CIN) is a well-known and important side effect to the use of contrast media when 
performing coronary angiography (CAG) or percutaneous 
coronary intervention (PCI). Defined as a relative increase in 
serum creatinine of ≥25% or an absolute rise of ≥44 μmol/L, 
this complication is low (<3%) in patients without known 
renal dysfunction or renal risk factors, whereas it is ≤50% 
in patients with known renal risk factors and dysfunction.1–3 
In case of primary PCI, the risk of CIN is 10% to 20%.4–6 
Usually, CIN develops within the first 2 to 3 days with a peak 
in serum creatinine level 3 to 5 days after contrast exposure. In 
general, serum creatinine normalizes within 7 to 10 days after 
contrast exposure. However, in patients with ST-segment–
elevation myocardial infarction (STEMI), after primary PCI 
the impaired renal function might persist in almost half of the 
patients with CIN.7 The effect of contrast media on renal func-
tion is complex and not fully understood. Initially, a reduction 
in glomerular filtration occurs because of changes in intrarenal 
and systemic regulatory mechanisms.8 Furthermore, an endo-
thelial dysfunction, an erythrocyte aggregation with increased 
viscosity, and a decreased erythrocyte velocity are followed 
by a decreased oxygen tension together with a directly toxic 
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effect on the tubular apparatus contributing to the reduction 
in renal function.9 In patients with normal renal function and 
no renal risk factors, a transient increase in serum creatinine 
in general is spontaneously normalized.10 However, this is not 
the case for patients with known reduced renal function or 
renal risk factors where a permanent reduction in renal func-
tion and a poorer prognosis may be the consequence.11 To 
avoid these serious side effects of contrast administration, 2 
precautions in general are recommended, namely to reduce 
the dose of contrast media as much as possible3 and to ensure 
optimal hydration before and immediately after the procedure 
by administration of intravenous sodium chloride.12 In addition 
to these general recommendations, several more specific phar-
macological interventions have been proposed for the protec-
tion of renal function. Among these, antioxidant treatment with 
N-acetylcysteine (NAC) has been investigated in several tri-
als without uniform results,13,14 as well as intravenous sodium 
bicarbonate (NaHCO3), which seems to prevent further dete-
rioration in renal function in patients with known reduced kid-
ney function.15,16 Patients treated for STEMI with primary PCI 
are most often exposed for contrast media without preexisting 
knowledge of renal function, and the patients are in different 
conditions of hydration. Only a few studies7,11,17 have inves-
tigated this problem in different settings. To investigate the 
degree of renal impairment and the possible preventive effect 
of NAC and intravenous NaHCO3, alone or in combination, we 
initiated the present randomized and prospective study.
Methods
Study Design
The study was designed as a randomized multicenter, open-labeled, 
4-arm study where patients were randomly assigned in a 1:1:1:1 ratio 
into 4 groups: (1) standard treatment with intravenous sodium chlo-
ride (0.9%) alone giving ≥60 mL/h for a minimum of 6 hours, (2) stan-
dard treatment+NAC 1200 mg orally before PCI followed by 1200 
mg daily during the next 48 hours, (3) standard treatment+isotonic 
NaHCO3 (167 mmol/L) intravenously as 500 mL in the first hour fol-
lowed by infusion of 100 mL per hour in the next 5 hours (in total 
1000 mL), and (4) standard treatment+NAC as in group 2+isotonic 
NaHCO3 intravenously as in group 3. Serum creatinine was measured 
at admission (day 0), the next morning (day 1), and the following 2 
days (day 2 and day 3). Finally, the serum creatnine was measured at 
day 30 after the index procedure (Figure 1).
Patients
From May 2010 to March 2012, patients for the study were re-
cruited from the 3 university hospitals in Western Denmark: Odense 
University Hospital, Aarhus University Hospital, Skejby, and Aalborg 
University Hospital. Eligible patients were all individuals aged ≥18 
years being admitted for STEMI and having primary PCI performed 
within 12 hours from the onset of chest pain. Excluded from partici-
pation in the study were patients in cardiogenic shock, being uncon-
scious, ventricular fibrillation or cardiac arrest before primary PCI, 
malignant disease, severe infection, or chronic treatment with dialy-
sis. Excluded from the study after enrollment were patients having 
cardiac surgery or any other major surgery within 30 days after index 
PCI, or a new contrast media examination (ie, CAG or PCI) within 
30 days. All patients were asked for participation after CAG when the 
indication for PCI was confirmed. Written informed consent was ob-
tained before PCI. The study was approved by the Danish Medicines 
Agency (EUDRACT no. 2009-017642-32) and the Scientific Ethical 
Committee for Southern Denmark (jr. no. S-20090149).
Primary PCI
This was performed according to a common protocol for all 3 hospi-
tals. The catheterization laboratory was notified when the diagnosis of 
STEMI was established, whether in the prehospital phase (tele-ECG 
transmission), at the referring hospital, or in the emergency room in 
1 of the 3 university hospitals. All patients were admitted directly to 
the catheterization laboratory. All patients were pretreated with aspirin 
600 mg, clopidogrel 300 mg or ticagrelor 180 mg, and heparine 10 000 
IU. At the discretion of the PCI operator, this treatment was supple-
mented by glycoprotein IIB/IIIA receptor inhibitor or bivalirudine. The 
STEMI diagnose was ensured based on typical symptoms present <12 
hours, characteristic ECG changes with ST-segment–elevation (≥0.1 
mV in ≥2 standard leads or v4 through v6 or ≥0.2 mV in ≥2 contigu-
ous precordial leads [v1 through v3]), or a presumed new developed 
left bundle branch block. Patients not belonging to the intake areas of 
the university hospitals were usually discharged within 24 hours to 
their local hospital, where the study-related blood test was taken at day 
2 and day 3. For the 30-day serum creatinine blood sample test, a labo-
ratory requisition was send to the patients 3 weeks after enrollment, 
and the patients had this blood test taken at a local hospital.
Randomization
Patients were enrolled by the investigators and randomly allocated 
to treatment groups after diagnostic CAG and before PCI. Block 
randomization by center was used to assign patients in a 1:1:1:1 
to (1) standard treatment with intravenous sodium chloride (0.9%) 
alone, (2) standard treatment+NAC 1200 mg orally before the PCI 
followed by 1200 mg daily during the next 48 hours, (3) standard 
treatment+isotonic NaHCO3 intravenously as 500 mL in the first hour 
WhAT IS KNOWN
•	Contrast-induced nephropathy is a serious condition 
in patients with ST-segment–elevation myocardial 
infarction treated with primary percutaneous coro-
nary intervention.
•	Usually, contrast-induced nephropathy develops 
within the first 2 to 3 days with a peak in serum cre-
atinine level 3 to 5 days after contrast exposure.
•	To avoid these serious side effects of contrast admin-
istration, 2 precautions in general are recommended 
to reduce the dose of contrast media as much as pos-
sible and to ensure optimal hydration before and im-
mediately after the procedure.
WhAT ThE STUDY ADDS
•	Contrast-induced nephropathy occurred overall in 
21.9% patients with no significant difference between 
4 prophylactic regimes (1) N-acetylcysteine, (2) so-
dium bicarbonate infusion, (3) N-acetylcysteine in 
combination with sodium bicarbonate, or (4) hydra-
tion with sodium chloride infusion alone.
•	An increase in serum creatinine >25% from the 
baseline value to 30 day was significantly lower in 
patients treated with combined N-acetylcysteine and 
sodium bicarbonate.
•	Contrast-induced nephropathy at day 3 did not dif-
fer significantly among patients with (creatinine 
clearance ≤60 mL/min) or without reduced creati-
nine clearance (creatinine clearance >60 mL/min) at 
baseline.
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followed by infusion of 100 mL per hour in the next 5 hours (in total 
1000 mL), and (4) standard treatment+combined NAC (as in group 
2)+isotonic NaHCO3 intravenously (as in group 3). An independent 
organization computer generated the allocation sequence, stratified 
by sex and presence of diabetes mellitus. Patients were assigned to 
treatment through a Web-based Trial Partner randomization system. 
Although operators were not blinded, all individuals analyzing data 
were masked to treatment assignment.
End Points
The primary end point of the present study was CIN defined as a rise 
in serum creatinine of ≥25% from baseline value at admission to the 
value at day 3 (48–72 hours) after the index procedure. Secondary 
end points were (1) changes in serum creatinine from day 3 to day 
30, (2) changes in serum creatinine from admission to day 30, (3) 
increase in serum creatinine of >25% from day 0 to day 30, and (4) 
increase in serum creatinine of >25% from day 0 to day 3 with a per-
sistent increase in serum creatinine of >25% at day 30 compared with 
day 0. Intention-to-treat analyses were conducted after 3 days and 
30 days of follow-up. Data monitoring was performed by the Good 
Clinical Practice unit at Odense University Hospital. An independent 
event committee, which was blinded to treatment group assignment 
during the adjudication process, reviewed all end points and source 
documents to adjudicate causes of death, reasons for hospitalization, 
diagnosis of myocardial infarction. Cine films were reviewed in the 
event committee to classify stent thrombosis and target vessel revas-
cularization (either with PCI or coronary artery bypass grafting).
Definitions
The study end points were defined as follows:
  CIN: a rise in serum creatinine of ≥25% from baseline value at 
admission to the value at day 3 (48–72 hours) after the index pro-
cedure. In patients who developed CIN, persistent renal damage 
was defined as persistence of increase in serum creatinine of ≥25% 
from baseline value at admission to the value at day 30.
The modification of diet in renal disease formula18 was used to cal-
culate the estimated creatinine clearance=186×standardized serum- 
creatinine−1.154×age−0.203×0.742 (if women).
Statistical Analysis
The number of patients included in the study was based on previous 
trials with NAC and NaHCO3. We assumed a rate of CIN of ≥25% in 
patients with hydration with sodium chloride only, 15% in patients 
treated with NAC, 8% in patients treated with NaHCO3, and 4% in 
patients treated with combined NAC and NaHCO3. To test this ex-
pected response with a power of 80%, a minimum of 125 patients in 
each of the 4 treatment groups had to be included. Thus, a minimum 
of 150 patients in each treatment group was prespecified for enroll-
ment to compensate for withdrawal of consent or cardiac events with 
or without contrast within 30 days. Distributions of continuous vari-
ables in the 4 groups of patients, NAC, isotonic NaHCO3, combined 
NAC+isotonic NaHCO3, and standard treatment with saline, were 
compared using the Kruskal–Wallis test. Distributions of categorical 
variables were compared using the χ2 test (primary end point: CIN 
defined as a rise in serum creatinine of ≥25% from baseline value 
at admission to the value at day 3). Serial creatinine concentrations 
and creatinine clearance were compared (secondary end point) within 
(index compared with day 3 and day 30, respectively) and between 
groups (at each time point) using a Kruskal–Wallis test. To account 
for multiple comparisons, the Bonferroni correction was used. Three 
treatments were compared with standard; thus a significance level 
of 0.05/3=0.017 was used for pairwise comparisons. The statistical 
analysis was performed using SPSS version 20.0.
Results
In total, 720 patients were enrolled and randomized, 5 patients 
were excluded because of withdrawal of consent. The patient 
characteristics were similar between the 4 groups (Table 1). 
Lesion characteristics and supplementary medication 
Enrolled and randomized (n=720) 
Withdrawal of consent (n=5)
N-Acetylcysteine (n=176)
Sodium bicarbonate (n=181)
N-Acetylcysteine + Sodium bicarbonate (n=177)
Standard (n=181)
Death (n=2)
New angiogram or intervention (n=24)
Death (n=4)
New angiogram or intervention (n=28)
Creatinine 48-72 h (n=644 (93%)) 
Creatinine 30 days (n=571 (87%)) 
Creatinine 48-72 h 
Creatinine 30 days 
Creatinine index 
Figure 1. Trial flow diagram.
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demonstrated no differences between the 4 groups (Table 2). In 
26 patients, the primary end point CIN within 3 days was not 
assessed (death=2, new angiogram/PCI n=24), and in another 32 
patients, the secondary end point with changes in serum creati-
nine from day 3 to day 30 was not assessed (death=4, new angio-
gram/PCI n=28). Baseline serum creatinine levels were obtained 
before angiography in 713 patients (99.7%). Serum creatinine 
levels were available at day 3 in 644 patients (93.4%), day 30 
in 571 patients (86.9%), and at all 3 time points in 536 patients 
(81.8%). The flow diagram of the trial is provided in Figure 1.
Contrast-Induced Nephropathy
Baseline renal function and volume of contrast medium did 
not differ significantly between the 4 groups (Tables 1 and 2). 
The primary end point CIN occurred overall in 141 (21.9%) 
patients with no significant difference between the 4 groups: 
NAC n=32 (20.1%) versus isotonic NaHCO3 n=33 (20.1%) 
versus combined NAC+isotonic NaHCO3 n=33 (20.8%) ver-
sus standard treatment with sodium chloride n=43 (26.5%; 
P=0.430; Figure 2). CIN at day 3 did not differ significantly 
among patients with or without reduced creatinine clear-
ance at baseline: creatinine clearance >60 mL/min n=132 
(22.4%) versus creatinine clearance ≤60 mL/min n=9 (17.5%; 
P=0.360). The secondary end point, the change in serum 
creatinine concentration between admission (before angi-
ography), day 3, and day 30, is shown in Table 3. Increase 
in serum creatinine of ≥25% from day 0 to day 30 (second-
ary end point) was seen in 97 (17.0%) patients, with a sig-
nificant difference between the 4 groups: NAC n=28 (18.7%) 
versus isotonic NaHCO3 n=27 (19.1%) versus combined 
NAC+isotonic NaHCO3 n=13 (9.2%) versus standard treat-
ment with sodium chloride n=29 (21.3%; P=0.033). Com-
pared with standard therapy with sodium chloride, only 
treatment with combined NAC+isotonic NaHCO3 reduced the 
risk of increase in serum creatinine of ≥25% from day 0 to 
day 30 significantly (P=0.005), which was significant after 
Bonferroni correction (Figure 3). In patients who developed 
CIN, persistent renal damage occurred in 55 (48.2%): NAC 
n=15 (57.7%) versus isotonic NaHCO3 n=14 (56.0%) versus 
combined NAC+isotonic NaHCO3 n=8 (29.6%) versus stan-
dard treatment with sodium chloride n=18 (50.0%; P=0.150). 
At day 30, the creatinine value was measured in 571 patients, 
and the persistent renal damage in 55 patients constitutes 39% 
of all patients (n=141) with CIN within day 3. None of the 
patients had renal failure requiring dialysis.
Clinical Outcome
Within 3 days, 2 (0.3%) patients died (cardiac death), 3 (0.3%) 
patients had an acute definite stent thrombosis, 3 (0.3%) patients 
had a new myocardial infarction, 3 (0.3%) patients had a target 
lesion revascularization, and 4 patients (0.6%) had a target ves-
sel revascularization. Eleven patients (1.5%) had a new angio-
gram for a clinical reason without intervention and 9 (1.3%) 
patients had a nonculprit artery PCI. Two patients (0.3%) had 
pulmonary edema within 24 hours; both patients were ran-
domized to treatment with combined NAC+isotonic NaHCO3. 
Within 30 days, 6 (0.6%) patients died (cardiac death), 3 (0.3%) 
patients had an acute definite stent thrombosis, 1 (0.1%) patient 
had a subacute definite stent thrombosis, 6 (0.6%) patients had a 
new myocardial infarction, 7 (1.0%) patients had a target lesion 
revascularization, and 11 patients (1.5%) had a target vessel 
revascularization. Twenty patients (2.8%) had a new angiogram 
for a clinical reason without intervention, and 24 (3.3%) patients 
had a nonculprit artery PCI. A composite major adverse cardiac 
event rate (cardiac death, myocardial infarction, target vessel 
revascularization) at 30-month follow-up was 1.8%: NAC n=0 
Table 1. Characteristics of Patients
Valid  
Cases NAC NaHCO
3
NAC+NaHCO
3
Standard Treatment 
(Sodium Chloride) P Value
No. of patients, n 715 176 181 177 181
Male sex, n (%) 715 127 (72.2) 139 (76.8) 139 (78.5) 145 (80.1) 0.32
Age, y (interquartile range) 715 63.0 (55.0−70.8) 62.0 (52.0−75.0) 63.0 (53.5−73.0) 63.0 (55.0−72.0) 0.89
Smoking, n (%) 684 82 (48.8) 88 (51.2) 79 (46.5) 89 (51.1) 0.79
Body mass index, kg/m2 (interquartile range) 661 26.5 (24.3−29.4) 26.1 (24.4−28.9) 26.4 (24.3−29.7) 26.6 (24.2−29.6) 0.91
Diabetes mellitus, n (%) 715 15 (8.5) 17 (9.4) 19 (10.7) 18 (9.9) 0.91
Hypertension, n (%) 695 58 (34.5) 62 (35.6) 68 (38.6) 58 (32.8) 0.71
Previous coronary artery bypass grafting, n (%) 704 1 (0.6) 2 (1.1) 1 (0.6) 3 (1.7) 0.67
Previous percutaneous coronary intervention, n (%) 693 23 (13.7) 20 (11.4) 17 (9.7) 13 (7.5) 0.28
Previous myocardial infarction, n (%) 692 21 (12.5) 18 (10.3) 14 (8.0) 14 (8.0) 0.44
Lipid-lowering therapy, n (%) 693 39 (23.2) 41 (23.4) 46 (26.3) 45 (25.7) 0.88
Serum creatinine level, mg/dL 713 0.84 (0.71−0.97) 0.87 (0.74−1.01) 0.88 (0.74−1.00) 0.87 (0.74−1.03) 0.19
Serum creatinine level, μmol/L 713 74.0 (63.0−86.0) 77.0 (65.0−89.0) 78.0 (65.5−88.9) 77.0 (65.0−91.0) 0.19
eGFR, mL/(min 1.73 m2) 713 94.3 (76.7−109.8) 91.4 (75.7−110.5) 90.8 (76.5−107.8) 89.5 (76.4−105.3) 0.45
Hemoglobin A1c 660 0.057 (0.055−0.060) 0.058 (0.055−0.061) 0.058 (0.055−0.061) 0.058 (0.055−0.062) 0.49
Left ventricle ejection fraction, n (%) 647 50.0 (45.0−60.0) 50.0 (45.0−60.0) 50.0 (40.0−55.5) 50.0 (40.0−60.0) 0.39
Systolic blood pressure, mm Hg 667 130.0 (110.0−142.8) 130.0 (110.0−140.0) 130.0 (118.0−140.0) 120.0 (116.0−148.0) 0.96
Diastolic blood pressure, mm Hg 667 70.0 (60.0−80.0) 70.0 (60.0−80.0) 71.5 (60.0−80.0) 72.0 (60.0−80.0) 0.67
eGFR indicates estimated glomerular filtration rate; NAC, sodium bicarbonate; and NaHCO
3
, sodium bicarbonate.
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(0.0%) versus isotonic NaHCO3 n=6 (3.6%) versus combined 
NAC+isotonic NaHCO3 n=3 (1.7%) versus standard treatment 
with sodium chloride n=4 (2.2%; P=0.127).
Discussion
The present randomized, open-labeled study in patients with 
STEMI demonstrates an overall rise in serum creatinine >25% 
in 22% of the patients from admission to day 3 without any 
difference in patients treated prophylactic with NAC, NaHCO3, 
NAC+NaHCO3, or hydration with sodium chloride. How-
ever, at 30 days, the group treated with the combination of 
NAC+NaHCO3 had a significantly lower rate of increase in 
serum creatinine >25% compared with standard treatment, or 
treatment with either NAC or NaHCO3 alone. After 30 days, 
half of the patients with CIN had persistent impaired renal func-
tion. Although patients in cardiogenic shock, severe general or 
Table 2. Procedure Characteristics
Valid Cases N-Acetylcysteine
Sodium  
Bicarbonate
N-Acetylcysteine+Sodium 
Bicarbonate
Standard Treatment 
(Sodium Chloride) P Value
No. of patients, n 715 176 181 177 181
Multivessel disease, n (%) 715 69 (39.2) 57 (31.5) 60 (33.9) 70 (38.7) 0.35
Infarct-related artery, n (%) 711 0.62
Left anterior descending 
artery, n (%)
73 (41.5) 76 (42.2) 83 (47.2) 78 (43.6)
Left circumflex artery, 
n (%)
23 (13.1) 26 (14.4) 27 (15.3) 29 (16.2)
Right coronary artery, 
n (%)
80 (45.5) 77 (42.8) 65 (36.9) 69 (38.5)
Left main, n (%) 0 (0.0) 1 (0.6) 1 (0.6) 3 (1.7)
Anterior STEMI or  
BBBMI, n (%)
674 63 (38.6) 73 (42.5) 82 (48.2) 71 (42.0) 0.26
Killip class, n (%) 715 0.35
  I 160 (98.2) 169 (98.3) 160 (94.1) 163 (96.4
  II 2 (1.2) 2 (1.2) 8 (4.7) 4 (2.7)
  III 1 (0.6) 1 (0.6) 2 (1.2) 2 (1.2)
Preintervention  
TIMI flow, n (%)
711 0.17
  Grade 0 96 (54.5) 83 (46.1) 90 (51.1) 91 (50.8)
  Grade 1 11 (6.2) 14 (7.8) 20 (11.4) 15 (8.4)
  Grade 2 31 (17.6) 27 (15.0) 16 (9.1) 29 (16.2)
  Grade 3 38 (21.6) 56 (31.1) 50 (28.4) 44 (24.6)
Sapheneous vein graft, n (%) 711 0 (0.0) 1 (0.6) 1 (0.6) 0 (0.0) 0.57
Stent number, n (%) 715 0.29
  0 14 (8.0) 10 (5.5) 14 (7.9) 12 (6.6)
  1 126 (71.6) 142 (78.5) 145 (81.9) 132 (72.9)
  2 33 (18.8) 23 (12.7) 17 (9.6) 33 (18.2)
  3+ 3 (1.7) 3 (3.4) 1 (0.6) 4 (2.3)
Drug-eluting stent, n (%) 715 151 (85.8) 152 (84.0) 152 (85.9) 155 (85.6) 0.68
Final TIMI flow, n (%) 711 0.81
  Grade 0 3 (1.7) 1 (0.6) 2 (1.1) 3 (1.7)
  Grade 1 0 (0.0) 1 (0.6)) 0 (0.0) 1 (0.6)
  Grade 2 3 (1.7) 5 (2.8) 7 (4.0) 7 (3.9)
  Grade 3 170 (96.6)) 173 (96.1) 167 (94.9) 168 (93.9)
Procedure time, min 
(interquartile range)
715 19.0 (13.0−29.0) 18.0 (13.0−25.0) 19.0 (13.0−27.0) 18.8 (12.0−26.0) 0.566
Contrast, mL (interquartile 
range)
699 140.0 (110.0−180.0) 130.0 (110.0−180.0) 140.0 (110.0−180.0) 150.0 (110.0−180.0) 0.51
Glycoprotein IIb/IIIa 
receptor blocker, n (%)
715 68 (38.6) 68 (37.6) 81 (45.7) 78 (43.1) 0.37
Bivalirudin, n (%) 650 59 (37.8) 63 (38.0) 57 (35.4) 61 (36.5) 0.96
Thrombectomy, n (%) 715 41 (23.3) 39 (21.5) 43 (24.3) 40 (22.1) 0.93
BBBMI indicates bundle branch block myocardial infarction; STEMI, ST-segment–elevation myocardial infarction; and TIMI, thrombolysis in myocardial infarction.
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infectious disease, and dialysis-treated patients were excluded 
in the present study, the overall average rise in serum creatinine 
>25% from admission to day 3 was of the same magnitude as 
found by others in patients with STEMI.4,7,17 The reason for con-
trast-induced renal impairment still remains unclear, but vaso-
constriction because of tubular damage and oxidative stress, 
which together with increased interstitial renal pressure, lead 
to medullary hypoperfusion, and lowered glomerular filtration 
may contribute significantly.19 These changes occur because of 
cytotoxity and increased viscosity of the contrast media. In the 
present study, almost all patients had Iodixanol (visipaque), a 
nonionic, dimeric, and iso-osmolar contrast medium, which 
is shown to have a low nephrotoxic effect in different subsets 
of patients with or without impaired renal function,20,21 but 
the matter of which type of contrast media that is most kid-
ney-friendly is still under debate.22 The relationship between 
impaired renal function after contrast media and prognosis has 
been well documented with a poorer prognosis for an impaired 
kidney function, as well in patients with precontrast-impaired 
kidney function.23–25 Many efforts have, therefore, been done 
to find regimens or drugs to prevent CIN. To find an effective 
prevention of CIN is, in particular, important in patients with 
STEMI treated with primary PCI in whom knowledge of pos-
sible kidney risk factors or disease is not present before inject-
ing contrast media to the coronary arteries. In the present study, 
we have examined the preventive effect on the kidney function 
using either NAC, NaHCO3, or both and compared the possible 
efficacy to standard treatment with sodium chloride intrave-
nously alone. In addition, the use of contrast media was reduced 
as much as possible, being in average 140 mL per procedure, 
because of the fact that the degree of impaired kidney function 
is depending on the dose of contrast used.26 In accordance with 
the previous studies,12,27 our patients in the standard group and 
in the NAC group did have a sodium chloride infusion to keep 
them well hydrated during and after the PCI procedure, whereas 
this was done by isotonic NaHCO3 in the other 2 groups. NAC 
Table 3. Change in Serum Creatinine and Creatinine Clearance
Index Day 3 Day 30 P Value
Serum creatinine, μmol/L
NAC, median (interquartile range) 74.0 (63.3−85.8) 80.0 (68.0−92.8) 81.5 (69.0−92.0) <0.001
NaHCO
3
, median (interquartile range) 78.5 (65.0−89.0) 84.0 (72.0−95.8) 81.5 (72.3−96.8) <0.001
NAC+NaHCO
3
, median (interquartile range) 77.0 (66.0−88.0) 86.0 (75.0−98.0) 82.0 (73.3−93.0) <0.001
Standard treatment (sodium chloride), median  
(interquartile range)
77.0 (65.0−90.0 83.0 (73.0−99.0) 82.0 (73.0−97.0) <0.001
P value 0.467 0.063 0.546
Creatinine clearance, mL/min
NAC, median (interquartile range) 94.9 (76.8−109.6) 85.1 (73.9−97.0) 82.8 (73.8−96.4) <0.001
NaHCO
3
, median (interquartile range) 89.8 (76.1−108.4) 81.6 (70.5−93.7) 81.5 (69.0−99.1) <0.001
NAC+NaHCO
3
, median (interquartile range) 92.2 (76.5−107.6) 81.1 (69.9−93.0) 82.7 (73.5−95.8) <0.001
Standard treatment (sodium chloride) median,  
(interquartile range)
90.9 (77.5−103.8) 80.2 (68.8−94.7) 81.8 (67.3−94.9) <0.001
P value 0.881 0.414 0.948
NAC indicates N-acetylcysteine; and NaHCO
3
, sodium bicarbonate.
Figure 2. Rate of contrast-induced nephropathy 
at day 3 in patients treated with N-acetylcysteine 
(NAC), isotonic sodium bicarbonate (NaHCO3), 
combined NAC+isotonic NaHCO3, and standard 
treatment with sodium chloride.
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is a potent antioxidant and by this supposed to prevent a direct 
oxidative tissue damage in the kidney.28 A possible beneficial 
clinical effect has been investigated in several studies in patients 
with chronic nephropathy showing different results.13,29,30 Only 
in 2 studies, the effect has been investigated in patients with 
primary PCI.5,30 In agreement with the results from the pres-
ent study, no beneficial effect on the occurrence of CIN using 
high-dose NAC could be proven, although patients in the 
study of Thiele et al5 included severely ill patients in hemody-
namic deranged condition. Thiele et al5 found an occurrence of 
CIN in 14% of NAC-treated patients, despite using a slightly 
higher contrast volume and enrolling patients in Killip class 4 
and patients treated with intra-aortic balloon pump. Whether 
patients with cardiogenic shock may benefit more from treat-
ment with NAC cannot be addressed from the data from the 
study by Thiele et al5 or our studies.
NaHCO3 is an alkalinizing agent with alkalinizing effect 
on the renal tubular fluid and is by this theoretically able to 
reduce oxidative tissue damage in the kidney induced by con-
trast media. In patients with STEMI, a regimen with prepro-
cedure and postprocedure hydration therapy with NaHCO3 
appeared to be more efficacious than postprocedure hydration 
only with isotonic sodium chloride.27 This is in accordance 
with our study. Although we did not find a significant reduc-
tion in CIN in NaHCO3-treated patients, the rate of CIN was 
numerically lower in NaHCO3-treated patients compared with 
patients hydrated with sodium chloride only. Furthermore, 
Merten et al15 demonstrated in a randomized setting, comparing 
hydration with isotonic sodium chloride or isotonic NaHCO3 in 
patients with impaired renal function undergoing either CAG or 
PCI, a significant reduction of CIN from 13.8% in the sodium 
chloride group to 1.7% in the NaHCO3 group. This is in contrast 
to our results, but patients characteristics were different because 
the patients enrolled in our study did not have a known impaired 
renal function and the hydration protocols differed with respect 
to the hydration with sodium chloride.
From a theoretical point of view, the combination of NAC 
and NaHCO3 might be the superior strategy because these drugs 
in combination may exert a potent antioxidative effect and by 
this reduce the harmful consequence of contrast media. In the 
present study, this could not be proven in the acute phase after 
primary PCI, but at long-term follow-up at 30 days, a signifi-
cant reduction in serum creatinine was observed in the group 
with NAC+NaHCO3 compared with standard treatment. A 
similar beneficial result has been reported by Briguori et al16 
in patients with chronic kidney disease, where a significantly 
lower proportion of patients with CIN was observed in the 
group treated with NAC+NaHCO3 compared with the group 
treated with isotonic sodium chloride+NaHCO3 2 days after 
contrast exposure. A meta-analysis reviewing 10 randomized 
controlled studies, mostly in patients with chronic kidney dis-
ease, showed significantly fewer patients with CIN in the group 
with NAC+NaHCO3 compared with sodium chloride+NaHCO3 
when defined as an increase of 0.5 mg/dL but not when defined 
as a 25% increase in serum creatinine.31 A beneficial effect of 
intravenous NaHCO3+NAC was also demonstrated in the study 
of Recio-Mayoral et al32 in patients undergoing PCI for acute 
coronary syndromes, showing a significant lower occurrence of 
CIN within the first week after index PCI. In that study, CIN was 
defined as an increase in serum creatinine of >0.5 mg/dL, but the 
protective effect was also present using the definition for CIN 
as an increase in serum creatinine of >25% from baseline. In a 
recent study by Leone et al,33 a group of urgent PCI patients had 
kidney protection with high-dose NAC+NaHCO3 and was com-
pared with a historic control group being treated with high-dose 
NAC+isotonic sodium chloride. Defining CIN as an increase 
of >25% in serum creatinine, they found a significant reduc-
tion in both in-hospital death and occurrence of CIN, the latter 
reduced from 14.1% to 8.0% 2 days after contrast exposure by 
the treatment with NAC+NaHCO3. In the present study, we did 
not observe any difference at 3 day but first at 30-day  follow-up. 
The reason for this is unexplained, and this secondary end point 
result is hypothesis generating and merits formal confirmation. 
Also, after 30 days, overall one fifth of the patients had impaired 
renal function, and half of the patients with CIN had persistent 
impaired renal function. The same was found in a retrospective 
Figure 3. Rate of >25 increase in serum after 30 
days compared with baseline in patients treated 
with N-acetylcysteine (NAC), isotonic sodium 
bicarbonate (NaHCO3), combined NAC+isotonic 
NaHCO3, and standard treatment with sodium 
chloride.
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observational registry,7 where half of the patients with CIN 
within 2 days had persistent impaired renal function, and these 
patients experienced more adverse clinical events that patients 
who did not develop CIN. Recently Maioli et al34 found that 
persistent renal damage occurred in ≈20% of patients 3 months 
after contrast exposure in patients with reduced creatinine clear-
ance at the time of the contrast exposure. This may indicate that 
CIN is not always a transient impairment of the renal function 
but rather a direct cause of worsening renal function.
Limitations
Like most PCI trials, the Prevention of Contrast-induced 
Nephropathy in Patients With ST-Segment Elevation Myocar-
dial Infarction Undergoing Primary Percutaneous Coronary 
Intervention (CINSTEMI) trial was designed as a  single-blinded 
study, but we think that the lack of  double-blindness would not 
influence the results because all end points were objective and 
determined by an event committee, who was blinded to treat-
ment group assignment during the adjudication process. The 
diagnostic angiogram was performed just before the random-
ization and initiation of the prophylactic treatment. However, 
we do not think that this treatment of prophylactic regimes 
delay of minutes would have influenced on the results in a 
STEMI population. Patients in cardiogenic shock or with pre-
hospital cardiac arrest were excluded from the study because 
these clinical circumstances by themself may influence creati-
nine levels the first days after the index primary PCI. Because 
we excluded these patients, the results from the CINSTEMI 
cannot be extrapolated to patients with STEMI and cardio-
genic shock or prehospital cardiac arrest. In a population with-
out known renal insufficiency, the baseline creatinine level 
would be expected to be lower compared with patients with 
preexisting renal insufficiency. With the end point definition 
used in the present study, which is comparable with the lit-
erature, a 25% increase in serum creatinine at day 3 requires 
a smaller absolute increase in patients with a normal or low 
baseline creatinine compared with patients with renal insuf-
ficiency or increased creatinine level. In this way, our study 
differs from studies where patients with known renal insuffi-
ciency are examined, and our results cannot be extrapolated to 
a population with known renal insufficiency. Furthermore, the 
results in the present STEMI population cannot be generalized 
to patients with stable angina pectoris, where proper lead times 
could be available for treatment with prophylactic regimes.
Conclusions
Treatment with NAC or NaHCO3 did not reduce the rate of 
acute CIN significantly. However, combined treatment with 
NAC and NaHCO3 may reduce the risk of renal dysfunction 
after 30 days.
Appendix
Please see the Data Supplement for additional information regarding 
CINSTEMI.
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